Germany · Delayed Price · Currency is EUR Drägerwerk AG & Co. KGaA Earnings Call Transcripts
Fiscal Year 2026
-
EBIT and Free Cash Flow rose sharply in Q1 2026, with strong sales growth and improved margins. Both divisions contributed to higher earnings, and guidance for the year remains positive, with no material impact expected from tariffs or geopolitical risks.
-
The company reported record sales and margin growth in 2025, driven by strong operational performance and innovation in open medical ecosystems. Defense and Safety segments are set for significant expansion, while margin improvement will rely on top-line growth, pricing, and cost control.
Fiscal Year 2025
-
Record net sales and EBIT were achieved in 2025, with both divisions and all regions contributing to growth. Despite significant tariff and currency headwinds, profitability improved, and strong cash flow supported higher dividends and reduced debt.
-
Strong order intake and sales growth drove robust earnings in the first nine months of 2025, with both Medical and Safety divisions contributing. Guidance was raised to the upper end of the range, though FX and regional headwinds remain risks.
-
H1 2025 saw stable net sales and strong order intake, but EBIT declined due to the absence of prior year one-offs and currency/tariff headwinds. Guidance for 2025 is confirmed, with management confident in margin improvement despite ongoing challenges.
-
Q1 2025 saw robust order intake and improved cash flow, with the safety division outperforming medical. EBIT and margins declined year-over-year due to higher expenses, but annual guidance is confirmed. Currency volatility and U.S. tariffs present ongoing risks.
Fiscal Year 2024
-
Profitability improved in 2024 with EBIT up 17% and stable sales, despite a sharp China decline. Outlook for 2025 is cautious, with 1%-5% sales growth and EBIT margin of 3.5%-6.5% expected. Dividend will rise, and both divisions are set to contribute to growth.
-
Order intake and net sales remained robust in the first nine months of 2024, with the safety division outperforming the medical division, which was impacted by weak demand in China. One-time gains from asset sales boosted EBIT, and full-year guidance is confirmed with strong Q4 expected.
-
H1 2024 saw solid performance with EBIT and margins up, driven by strong Safety Division growth and one-off gains, while Medical Division faced headwinds from China. Full-year guidance was confirmed but with a more cautious outlook for China and continued focus on profitability and innovation.